Periodontal inflammation as a potential driver of HIV low level viremia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
06
03
2024
accepted:
02
06
2024
medline:
17
6
2024
pubmed:
17
6
2024
entrez:
17
6
2024
Statut:
epublish
Résumé
HIV can be successfully suppressed to undetectable levels by antiretroviral therapy (ART) in most people with HIV (PWH). However, a small proportion continues to have persistent low-level viremia (LLV) during ART. A presumed source of LLV is production or replication from viral reservoirs, which are maintained in the presence of ART. It is unknown whether the oral cavity can be considered an HIV reservoir. As periodontal inflammation is a common problem in PWH, we hypothesize that periodontal inflammation in the oral cavity activates (latently) infected cells and thus might be associated with LLV. We included 11 individuals with HIV LLV, and compared HIV-RNA levels in saliva and plasma at baseline and at week 24 after switch of ART. We compared the LLV-group at baseline with 11 age-matched controls with suppressed viremia. To investigate the severity of periodontitis we used Periodontal Inflamed Surface Areas (PISA) by measuring probing depth, gingival recession, bleeding on probing and clinical attachment level. Severity of periodontitis was classified according to the CDC-AAP case definition. Additional insights in periodontal inflammation were obtained by comparing immune activation markers and the presence of periodontal pathogens. In four individuals of the LLV group, residual levels of HIV-RNA were detected in saliva at baseline (N = 1) or at week 24 (N = 2) or both (N = 1). Of the four individuals with LLV, three had residual levels of HIV-RNA in saliva. All 22 individuals had moderate to severe periodontitis. PISA was not significantly different between cases with LLV and controls. Similarly, periodontal pathogens were frequently observed in both groups. Total activated HLA-DR+CD38+ CD4+ cells and CD8+ cells were significantly higher in the LLV group than in the control group (p = <0.01). No immune markers were associated with LLV. In conclusion, periodontal inflammation is an unlikely driver of HIV LLV compared to HIV suppressed individuals.
Identifiants
pubmed: 38885222
doi: 10.1371/journal.pone.0305641
pii: PONE-D-24-08271
pmc: PMC11182545
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0305641Informations de copyright
Copyright: © 2024 Stam et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist
Références
J Periodontal Implant Sci. 2017 Oct;47(5):328-338
pubmed: 29093989
J Periodontol. 2018 Jun;89 Suppl 1:S9-S16
pubmed: 29926938
Top Antivir Med. 2022 Oct-Nov;30(4):559-574
pubmed: 36375130
J Infect Dis. 2011 Aug 15;204(4):515-20
pubmed: 21791652
Int J Mol Sci. 2021 Jul 22;22(15):
pubmed: 34360589
Viruses. 2024 Jan 25;16(2):
pubmed: 38399959
Postgrad Med. 2018 Jan;130(1):98-104
pubmed: 29065749
Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):108-12
pubmed: 7506410
J Infect Dis. 2003 May 15;187(10):1534-43
pubmed: 12721933
Oral Microbiol Immunol. 1993 Dec;8(6):370-4
pubmed: 8152838
PLoS One. 2014 Apr 03;9(4):e93537
pubmed: 24699474
J Oral Microbiol. 2023 Apr 2;15(1):2197779
pubmed: 37025387
Rev Med Virol. 2023 Jan;33(1):e2400
pubmed: 36209388
Curr HIV/AIDS Rep. 2007 Feb;4(1):42-7
pubmed: 17338860
J Periodontol. 2007 Jul;78(7 Suppl):1387-99
pubmed: 17608611
J Periodontal Res. 2004 Jun;39(3):149-57
pubmed: 15102043
J Periodontol. 2022 Apr;93(4):613-620
pubmed: 34396525
J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):122-128
pubmed: 31110428
Otolaryngol Head Neck Surg. 1996 Apr;114(4):593-8
pubmed: 8643270
Clin Infect Dis. 2021 Jun 15;72(12):2079-2086
pubmed: 32271361
HIV Med. 2018 Apr 23;:
pubmed: 29687590
Oral Dis. 2006 May;12(3):219-28
pubmed: 16700731
Virology. 2015 Jan 1;474:65-81
pubmed: 25463605
J Periodontol. 2012 Dec;83(12):1449-54
pubmed: 22420873
Cell Immunol. 2011;268(2):105-11
pubmed: 21420664
J Dent Res. 2001 Feb;80(2):414-20
pubmed: 11332524
Clin Vaccine Immunol. 2010 Sep;17(9):1417-27
pubmed: 20610663
Virology. 2017 Oct;510:185-193
pubmed: 28750322
Int J Mol Sci. 2022 Jan 14;23(2):
pubmed: 35055069
J Antimicrob Chemother. 2014 Nov;69(11):3041-6
pubmed: 25011654
Biomed J. 2019 Feb;42(1):27-35
pubmed: 30987702
J Clin Microbiol. 1985 Jul;22(1):75-9
pubmed: 3926818
J Investig Clin Dent. 2018 Nov;9(4):e12351
pubmed: 30019446
Nat Rev Immunol. 2015 Jan;15(1):30-44
pubmed: 25534621
Exp Ther Med. 2014 Jul;8(1):323-327
pubmed: 24944641
Rev Med Virol. 2017 Mar;27(2):
pubmed: 28128885
J Dent Res. 2000 Jul;79(7):1496-501
pubmed: 11005734
AIDS. 2015 Jan 28;29(3):373-83
pubmed: 25686685
Oral Microbiol Immunol. 2009 Oct;24(5):401-7
pubmed: 19702954
J Clin Periodontol. 2015 May;42(5):407-12
pubmed: 25808877
Clin Oral Investig. 2023 Mar;27(3):1255-1263
pubmed: 36316604
J Infect. 2021 Mar;82(3):e17-e19
pubmed: 33347945
Ann N Y Acad Sci. 1993 Sep 20;694:72-7
pubmed: 8215087
Periodontol 2000. 2016 Feb;70(1):93-110
pubmed: 26662485
J Infect Dis. 2015 Aug 15;212(4):585-95
pubmed: 25722296
Oral Maxillofac Surg Clin North Am. 2014 Feb;26(1):35-53
pubmed: 24287192
J Infect. 2019 Mar;78(3):171-177
pubmed: 30528870
Front Immunol. 2023 Jan 30;14:1104423
pubmed: 36798134
J Clin Periodontol. 2008 Aug;35(8):668-73
pubmed: 18564145